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ABSTRACT
Gorham-Stout disease, a rare and intractable disease 
of unknown etiology, causes systemic bone lysis and 
replacement with lymphoid tissue. Here, we report a 
case of Gorham-Stout disease with cerebrospinal fluid 
leakage in a 16-year-old boy. The patient complained 
of nasal discharge, right ear obstruction, fever, and 
headache. A computed tomography scan of the head 
showed osteolysis around the right internal carotid 
artery, vestibule, and cochlea and osteolytic changes in 
the left parietal bone. It was suggested that the patient 
had bacterial meningitis owing to the leakage of cere-
brospinal fluid from the fistula caused by the temporal 
bone osteolysis. He was treated with meropenem, and 
a transmeatal fistula closure and a bone biopsy of the 
left parietal bone were performed. Intraoperatively, 
osteolysis was observed on the promontory and around 
the internal carotid artery. The fistula was closed by 
dense filling and compression around the fistula, in the 
middle ear cavity, and in the external auditory canal. 
The symptoms disappeared after the surgery. Bone 
biopsy showed the presence of a lymphangioma, and 
Gorham-Stout disease was diagnosed. Prophylactic 
bisphosphonate therapy was initiated. A 4-year follow-
up revealed no progression of the disease.
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Gorham-Stout disease (GS), a rare disease of unknown 
etiology, causes systemic bone lysis and replacement 
with lymphoid tissue. It is designated as an intractable 
disease in Japan, and no effective treatment has been 
established. In the head and neck region, osteolysis 
around the inner ear causes perilymphatic fistulas 
and cerebrospinal fluid (CSF) leakage. Perilymphatic 
fistulas cause complications, such as deafness and 
vertigo or dizziness, which are directly related to the 
patient’s quality of life, and CSF leakage could lead to 
meningitis, a potentially fatal complication. Since it 
is difficult to cure the disease, symptomatic treatment 
must be instituted. However, surgery is one of the most 
effective treatment methods, albeit with lower long-term 
efficacy. In this article, we aimed to report a case of GS 
disease with CSF leakage that was treated with fistula 
closure using a transmeatal approach and to describe 
the patient’s subsequent progress.
PATIENT REPORT
The patient was a 16-year-old boy with a history of 
bacterial meningitis at the age of 13 years. No relevant 
family history was noted. The patient was admitted to 
a hospital after he developed fever and headache, fol-
lowing a two-day history of a nasal discharge and right 
ear obstruction. A CSF analysis revealed a cell count of 
159 cells/μL. Therefore, viral meningitis was suspected. 
After the fever persisted, a second CSF examination on 
the fourth day of hospitalization revealed an elevated 
cell count of 544 cells/μL. Additionally, a glucose test 
around the pharyngeal opening of the Eustachian tube 
was positive, and CSF rhinorrhea was suspected. A 
computed tomography (CT) scan of the head showed os-
teolysis around the right inner ear canal and an isodense 
area in the tympanic cavity. It was suggested that the 
patient had bacterial meningitis due to CSF leakage, 
and meropenem therapy (2 g every 8 h) was initiated. 
The fever resolved, but the rhinorrhea persisted, thus the 
patient was transferred to our hospital for treatment on 
the 13th day of hospitalization.
The tympanic membrane of the right ear was swol-
len, and there was clear effusion in the tympanic cavity. 
CSF analysis revealed a decreased in cell count (25 
cells/μL, polymorphonuclear cells: 4%) compared to the 
pre-treatment count. The CSF cultures were negative 
(Table 1). Bone marrow examination revealed no evi-
dence of hematologic tumors that could cause osteolytic 
lesions. A CT scan of the temporal bone showed oste-
olysis around the right internal carotid artery, vestibule, 
and cochlea, as well as osteolytic changes in the left 
parietal bone. Although there was fluid in the mastoid 
cavity, no evidence of destruction was found within 
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the mastoid process (Figs. 1A, B and D). T2-weighted 
magnetic resonance imaging (MRI) of the head exhib-
ited relatively hyperintense areas around the right peri-
carotid canal, vestibule, cochlea, and the left parietal 
bone, which were seen as bone defects on the CT scan, 
suggesting osteolysis (Figs. 1C and E). A whole-body 
CT scan with contrast enhancement and radiography 
of the pelvis and extremities showed no osteolysis, and 
there was no pleural effusion or interstitial change in 
the lungs. In addition, there were no abnormal findings 
in the spleen or liver. Cerebrospinal scintigraphy using 
111In-diethylenetriaminepentaacetic acid (111In-DTPA) 
showed increased accumulation in the region corre-
sponding to the right mastoid, suggesting CSF leakage 
(Fig. 2).
We suspected GS disease based on the multiple, 
progressive, osteolytic changes seen on imaging. 
Therefore, we planned to close the CSF leakage, and 
at the same time, conduct a biopsy to exclude other 
diseases.
The patient was treated for meningitis with 
meropenem. After treatment for meningitis, the right 
transmeatal fistula closure was performed to prevent 
CSF leakage on day 29 of hospitalization. At the same 
time, a biopsy of the left parietal bone was performed to 
investigate the cause. The surgical approach was taken 
through a post-auricular incision. The subcutaneous 
connective tissue of the temporal region was harvested 
to use as an obstructive material for the fistula. A tym-
panomeatal flap was raised to check the inside of the 
tympanic cavity. Osteolysis was observed on the prom-
ontory and around the internal carotid artery. There was 
evidence of the pulsatile leakage of CSF in the middle 
ear. The fistula was obstructed with connective tissue 
and cartilage fragments of the cymba and was fixed 
with fibrin glue. In addition, the tympanic cavity was 
filled with cellulose sponge to prevent leakage, and the 
external auditory canal was densely filled with cellulose 
sponge to provide additional transmeatal pressure (Fig. 
3).
 The pathological findings in the biopsied parietal 
bone showed multiple large and small dilated vascular-
like structures in the bone lined by a single layer of 
endothelial-like cells (Fig. 4). D2-40 immunostaining 
was positive, although only partially, confirming 
the presence of lymphatic endothelial cells. Based 
on the clinical and pathological findings, the patient 
was diagnosed with GS disease. The symptoms of 
nasal discharge disappeared after the surgery, The 
administration of meropenem was discontinued on the 
second postoperative day, and treatment with sodium 
risedronate was started to control the progression of GS 
disease. As part of the follow-up, a whole-body CT scan 
was performed every year until the third postoperative 
year, and we continue to perform a temporal bone 
CT scan every year. Four years have passed since the 
surgery, and the patient is leading a normal life with no 
new findings related to osteolysis and no recurrence of 
CSF leakage.
DISCUSSION
 GS disease was first described by Gorham et al. in 1955 
as a disease causing “disappearing bones.”1 The disease 
is characterized by progressive osteolysis throughout 
the body, causing pain and bone fractures. It is also 
associated with lesions in the lungs, spleen, and other 
viscera and with a variety of symptoms depending on 
the affected organ. The pathogenesis of GS has not yet 
been elucidated, although it is thought that the osteolysis 
may be caused by mechanical compression of the bone 
owing to lymphatic hyperplasia or by the activation of 
osteoclasts by various factors.2, 3 Disease onset most 
commonly occurs in young age groups, but it has been 
reported across all age groups. To date, approximately 
100 cases of GS disease have been reported in Japan, 
including those with lymphangiomas.
Poor prognosis is associated with chest lesions, 
such as those caused by pleural effusion or chylothorax, 
but the prognosis for patients without chest lesions is 
good.4 However, it is impossible to predict whether the 
Table 1. Cerebrospinal fluid findings
The number of days since hospitalization 1 4 13 25
Opening pressure (mmH2O) 140 120 NA 100
Cell count/μL 159 544 25 9
Polymorphonuclear cells (%) 96 58 4 0
Protein (mg/dL) NA 59 39 NA
CSF to serum glucose ratio 0.65 0.53 0.59 NA
Culture NA Negative Negative NA
CSF, cerebrospinal fluid; NA, not available.
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Fig. 1. A, B, D: CT scan images of the temporal bone. C, E: MRI scan image. A: Osteolysis around the cochlea. The white arrowhead 
indicates osteolysis of the internal auditory canal. B: The black arrowhead indicates osteolysis around the internal carotid artery. There is 
fluid in the mastoid cavity. C: White arrow: The area around the right carotid artery periphery, vestibule, and cochlea showing relatively 
high signal intensity on T2-weighted MRI. D: Hypodense region of the left parietal bone (black arrow). E: White arrow: The left parietal 
bone showing a high signal intensity area on T2-weighted MRI. CT, computed tomography; MRI, magnetic resonance imaging.
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disease will resolve spontaneously or progress.
The main findings are as follows: a) localized or 
scattered lysis of the bone cortex or marrow; b) diffuse 
lymphangiomatous lesions or lymphatic effusion in the 
intrathoracic organs, such as the lungs, mediastinum, 
and heart; and c) diffuse lymphangiomatous lesions or 
lymphatic effusion in the intraperitoneal organs, such 
as the liver and spleen. Diagnosis can be confirmed 
when one or more of these three criteria are met, and 
when the pathological examination reveals irregularly 
dilated lymphoid tissue lined by lymphatic endothe-
lium. In some cases, spindle-shaped cells are present. 
Conversely, a diagnosis can also be confirmed when all 
other possibilities in the differential diagnosis (malignant 
neoplasm, congenital osteolytic disease, etc.) can be 
ruled out. Bone lesions can be diagnosed by radiography 
or CT, but changes in the bone marrow and the spread 
of the disease to the soft tissues should be confirmed 
by T2-weighted MRI. High-resolution CT and MRI are 
also useful for the evaluation of thoracic lesions.
Interferon,5 bisphosphonates,6 propranolol,7 
bevacizumab (anti-vascular endothelial growth factor 
therapy humanized monoclonal antibody),8 and mecha-
nistic target of rapamycin (mTOR) inhibitors9 have been 
reported as drug therapies, but none have been estab-
lished. Sirolimus, an mTOR inhibitor, is expected to be 
a new therapeutic agent, but it is still in the clinical trial 
stage in Japan and cannot be used easily.9 In addition, 
surgical treatment, radiotherapy, and a local injection 
of OK-432 have been reported as treatments for local 
lesions.10, 11 In particular, there are reports on the treat-
ment of pathological fractures by, repair, fixation, and 
bone grafting.12
In this case, the osteolysis in the right temporal 
bone and left parietal bone was used to differentiate the 
disease, and tissue biopsy was performed to confirm 
the diagnosis. Fistula closure with a surgical approach 
Fig. 2. Cerebrospinal scintigraphy using 111In-DTPA. White 
arrow: An increased accumulation in the area corresponding to 
the right mastoid, suggesting CSF leakage. 111In-DTPA, 111In-
diethylenetriaminepentaacetic acid; CSF, cerebrospinal fluid.
Fig. 3. Intraoperative findings. Left: Intraoperative photograph. Right: Illustrative intraoperative photographs. Cartilage fragments, 
connective tissue, and cellulose sponges filled in the tympanic cavity. A: anterior, P: posterior, S: superior, I: inferior. Blue:the malleus, 
yellow: chorda tympani, brown: connective tissue and cellulose sponge, green: annulus tympanicus.
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is considered essential for local control of persistent 
CSF leakage. The subcutaneous tissue of the temporal 
region, cartilage fragments, and cellulose sponges were 
used to tightly fill and compress the periphery of the 
fistula, the middle ear, and the external auditory canal. 
This allowed us to achieve closure without recurrence 
after the surgery. Other authors have reported closure 
of the fistula by using intratympanic fat filling and a 
Eustachian tube plug or by using fascia and periosteum 
in the middle cranial fossa approach.13, 14 In all of these 
reports, the patients progressed without relapses, there-
fore, the conventional methods of dealing with CSF 
leakage seem to be effective. Surgical closure of CSF 
leakage can be achieved using either the transmeatal or 
the middle cranial fossa approach. The middle cranial 
fossa approach is more invasive, and there is a risk of 
complications, such as seizures, loss of hearing, facial 
palsy, and infection.15 Therefore, we first adopted the 
less invasive and risky method of fistula closure with the 
transmeatal approach. The advantage of this approach 
is that when the area to be filled is small, a sufficient 
amount of filling material can be obtained from the 
same surgical site. In addition, the additional pressure 
from the external auditory canal with cellulose sponges 
may have contributed to some extent in reducing the 
CSF leakage, and we thought this would be an effective 
approach to try as an initial surgery. In this case, if the 
osteolysis around the inner ear had progressed, and 
there had been a recurrence of CSF leakage, it would 
have been difficult to perform an additional fistula 
closure from the side of the tympanic cavity. In such 
cases, it is necessary to consider another approach, 
such as the middle cranial fossa approach. In addition, 
bisphosphonates were used to prevent the progression 
of the disease, However, there were no new findings 
of osteolysis and no recurrence of CSF leakage in our 
patient. Since the patient has shown good progress, we 
plan to continue the same medication. However, it is 
Fig. 4. Histopathological findings of the left parietal bone. There are many large and small dilated vascular structures in the bone, and 
the inner surface is lined with endothelial-like cells (hematoxylin eosin staining). Bar = 500 μm.
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unclear whether this condition will remain stable and 
whether long-term medication is desirable. It is thought 
that strict follow-up will be necessary in the future.
In conclusion, we performed a transmeatal fistula 
closure in a patient with GS disease who had CSF leak-
age due to temporal osteolysis. The fistula was closed 
by dense filling and compression around the fistula, in 
the middle ear cavity, and in the external auditory canal. 
The patient was treated with bisphosphonates and has 
not shown progression of the disease, but regular and 
careful follow-up is required.
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